When Side Effects Become Therapies: A Mechanistic Taxonomy of Adverse Drug Reactions as Translational Signals for Drug Repositioning.

Fundamental & clinical pharmacology

Hormonal Contraception and Initiation of Semaglutide Therapy.

JAMA network open

Multi-target-directed drugs: new additions in 2025 and post-marketing safety surveillance of drugs marketed in 2022-2024.

Pharmacological reports : PR

Cost-Effectiveness of Endoscopic Bariatric Therapies Compared with Laparoscopic Sleeve Gastrectomy and Semaglutide.

Obesity surgery

Host-directed treatments for tuberculous meningitis utilizing a multi-platform approach across mouse and human models.

Nature communications

Association between GLP-1 receptor agonists and alcohol-related hospitalisations among adults with alcohol use disorder: multi-target trial emulation study.

BMJ open

From FLOW to translational positioning in chronic kidney disease: mechanistic complementarity of SGLT2 inhibitors and GLP-1 receptor agonists.

Translational research : the journal of laboratory and clinical medicine

GLP-1 Receptor Agonists as a Candidate Treatment for Opioid Use Disorder: From rats to humans.

Biological psychiatry

I've tested over 100 compounds since 2017 (peptides, shrooms, TRT, nicotine, etc.) to improve my health, performance, and focus. A short list of the ones that made the greatest impact: 1) GLP-1s (the heaviest hitters I've ever used) - Retatrutide - Tirzepatide - Semaglutide

The most popular peptides in the research and biohacking world right now: → BPC-157 (healing) → TB-500 (recovery) → Retatrutide (fat loss) → Semaglutide & Tirzepatide (fat loss) → CJC-1295 + Ipamorelin (growth hormone) → Semax & Selank (focus)

our full reptides peptide tier list: S: - tirzepatide - semaglutide - retatrutide - liraglutide - orforglipron - tesamorelin - hgh - hcg - ghk-cu A: - ss-31 - pt-141 - survodutide - mazdutide - sermorelin - bpc-157 - tb-500 - cjc+ipa - cjc-1295 - ipamorelin - bpc+tb -

HANGİ PEPTİT HANGİ AMAÇLA KULLANILIYOR? Retatrutide — obezite ve metabolik hastalık araştırmaları (GLP-1/GIP/Glukagon agonisti) Tirzepatide — kilo kaybı ve tip 2 diyabet araştırmaları Semaglutide — iştah kontrolü ve glukoz metabolizması Cagrilintide — iştah baskılama ve kilo https://t.co/xIQdvyfWVt

The next 2 weeks could be the biggest stretch of 2026 for $HIMS. There are 2 major catalysts investors should be watching and understand. 1) FDA Compounded Peptide Advisory Meeting First, this is not the FDA’s final decision. Here’s how it works: - Independent experts https://t.co/JDEyZ1iIkZ

Semaglutide and tirzepatide are often discussed as if they were interchangeable. They are not. Semaglutide targets the GLP-1 receptor. Tirzepatide targets both GIP and GLP-1 receptors, creating a different pharmacologic profile.

2/Despite discovering the first GLP-1 mechanism - semaglutide and later launching the first GLP-1 drugs Ozempic and Wegovy, Novo Nordisk $NVO has lost both its scientific and commercial leadership position in this lucrative $80B market after Eli Lilly’s $LLY lunched its own https://t.co/O76Ed3zOTv

Some acronyms you’ll see a lot in peptide discussions and what they mean: API: Active Pharmaceutical Ingredient = Basically the actual active peptide as opposed to fillers, stabilizers, or BAC water. Often used loosely to mean "the raw powder," though the powder isn't always